CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Hydroxocobalamin Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2024-11-04. Latest FDA row update: 2026-10-01.
FDA lists 2 package records, with companies: Actavis Pharma, Inc., BTG INTERNATIONAL INC., BTG International Inc., Teva Pharmaceuticals USA, Inc.. Package NDCs: 0591-2888-30, 50633-310-11.
FDA shortage reason: Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| BTG International Inc. | 50633-310-11 | Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11) | Limited Availability | 2026-10-01 |
| Teva Pharmaceuticals USA, Inc. | 0591-2888-30 | Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30) | Unavailable | 2026-10-01 |
Source facts
Grouped generic ingredient: Hydroxocobalamin Injection · 2 package records
Therapeutic categories: Other
Dosage forms: Injection
Routes: INTRAMUSCULAR, INTRAVENOUS
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.